|
Dr Martens PLC on Wednesday appointed general managers for all major markets, in an effort to streamline the company. The Northamptonshire, England-based boot maker framed the decision ‘as part of the approach to simplify the operating model in line with the new consumer-first strategy’. The updated ‘market level structure’ will allow Dr Martens ‘to be closer to the consumer’, it said, while shoring up global brand, technology and support functions. Dr Martens has promoted internal staff to the new general manager positions. It has appointed Nick Duff as UK GM, Nathalie Schneider as France GM, Giorgio Trevisan as Italy GM and Kristin Staeren as GM of the DACH market, which includes Germany, Austria and Switzerland. The company also noted that adidas AG alum Yoichi Oikawa recently joined Dr Martens as Japan GM. Paul Zadoff, president of Americas, continues to helm the USA division. Together, the six markets account for more than 80% of revenue, the company estimated. Alongside the new market structure, Dr Martens said it is simplifying its leadership through a new executive team. Chief Executive Ije Nwokorie will lead the team, which includes Chief Commercial Officer Mike Stopforth, to whom the new market GMs will report. Also in the executive team are Zadoff, Chief Financial Officer Giles Wilson, Chief Brand Officer Carla Murphy, interim Chief Operating Officer Anna Duffiet, Chief People Officer Bridget Jolliffe and Chief Legal Officer Katherine Bellau. CEO Nwokorie commented: ‘Over the past year we have reorganised our business and ways of working so that we are truly consumer-first, as opposed to channel-led. Nwokorie stressed that each member of the leadership team will help ’scale the business in the years ahead.‘ Back in January, the CEO called financial 2026 ’a year of pivot, as we make the necessary changes to our business to set us up for future sustainable growth‘. Dr Martens posted mixed third-quarter results, with growth in the Americas offset by weak performances in Europe, Middle East & Africa, and Asia Pacific. Revenue in the three months ended December 28 fell 3.1% on-year to £251 million, which would put year-to-date revenue 1.8% below the year prior on a reported basis. The company has forecast sales for financial 2026, which ended in March, broadly flat at constant currency, saying it is ’comfortable‘ with market expectations for pretax profit and that it expects the latter to show ’significant‘ yearly growth. In financial 2025, Dr Martens posted revenue of £787.6 million, reported pretax profit of £8.8 million and adjusted pretax profit of £34.1 million. Dr Martens shares rose 3.8% to 65.30 pence on Wednesday morning in London, having gained 33% over the past year. Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
